| HOME >> BIOLOGY >> TECHNOLOGY |
p>
beginning of
the period 3,491,511 3,511,357 6,923,889 7,224,307 -
-------------------------------------------------------------------------
Cash and cash
equivalents,
end of
the period 3,326,374 3,957,086 3,326,374 3,957,086 3,326,374
-------------------------------------------------------------------------
-------------------------------------------------------------------------
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
This discussion and analysis should be read in conjunction with the unaudited financial statements of Oncolytics Biotech Inc. as at and for the three and nine months ended September 30, 2007 and 2006, and should also be read in conjunction with the audited financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2006. The financial statements have been prepared in accordance with Canadian generally accepted accounting principles ("GAAP").
FORWARD-LOOKING STATEMENTS
The following discussion contains forward-looking statements, within
the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements, including our belief as to the
potential of REOLYSIN(R) as a cancer therapeutic and our expectations as to
the success of our research and development and manufacturing programs in
2007 and beyond, future financial position, business strategy and plans for
future operations, and statements that are not historical facts, involve
known and unknown risks and uncertainties, which could cause our actual
results to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the need for and
availability of funds and resources to pursue research and develop
'/>"/>
| SOURCE Oncolytics Biotech Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |